TY - JOUR T1 - Functional characterization of six <em>SLCO1B1</em> (OATP1B1) variants observed in Finnish individuals with a psychotic disorder JF - medRxiv DO - 10.1101/2022.08.10.22278615 SP - 2022.08.10.22278615 AU - Katja Häkkinen AU - Wilma Kiander AU - Heidi Kidron AU - Markku Lähteenvuo AU - Lea Urpa AU - Jonne Lintunen AU - Kati-Sisko Vellonen AU - Seppo Auriola AU - Minna Holm AU - Kaisla Lahdensuo AU - Olli Kampman AU - Erkki Isometsä AU - Tuula Kieseppä AU - Jouko Lönnqvist AU - Jaana Suvisaari AU - Jarmo Hietala AU - Jari Tiihonen AU - Aarno Palotie AU - Ari V. Ahola-Olli AU - Mikko Niemi AU - the SUPER-Finland researchers listed in the Acknowledgements Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/10/2022.08.10.22278615.abstract N2 - Aim Variants in the SLCO1B1 (solute carrier organic anion transporter family member 1B1) gene encoding the OATP1B1 (organic anion transporting polypeptide 1B1) protein are associated with altered transporter function that can predispose patients to adverse drug effects with statin treatment. We explored the effect of six rare SLCO1B1 single nucleotide variants (SNVs) occurring in Finnish individuals with a psychotic disorder on expression and functionality of the OATP1B1 protein.Methods The SUPER-Finland study has performed exome sequencing on 9,381 individuals with at least one psychotic episode during their lifetime. SLCO1B1 SNVs were annotated with PHRED-scaled Combined Annotation-Dependent (CADD) scores and the Ensembl variant effect predictor (VEP). In vitro functionality studies were conducted for the SNVs with PHRED-scaled CADD score &gt;10 and predicted to be missense. To estimate possible changes in transport activity caused by the variants, transport of 2’,7’-dichlorofluorescein (DCF) in OATP1B1 expressing HEK293 cells was measured. The amount of OATP1B1 in crude membrane fractions was quantified with a LC–MS/MS-based quantitative targeted absolute proteomics analysis.Results Six rare missense variants of SLCO1B1 were identified in the study population located in transmembrane helix 3: c.317T&gt;C (p.106I&gt;T), intracellular loop 2: c.629G&gt;T (p.210G&gt;V), c.633A&gt;G (p.211I&gt;M), c.639T&gt;A (p.213N&gt;L), transmembrane helix 6: 820A&gt;G (p.274I&gt;V), and the C-terminal end: 2005A&gt;C (p.669N&gt;H). Of these variants, SLCO1B1 c.629G&gt;T (p.210G&gt;V) resulted in protein loss of function, abolishing the uptake of DCF and reducing membrane protein expression to 31% of reference OATP1B1.Conclusions Of the six rare missense variants, SLCO1B1 c.629G&gt;T (p.210G&gt;V) causes loss-of-function of OATP1B1 transport and severely decreases membrane protein abundance. Carriers of SLCO1B1 c.629G&gt;T may be susceptible to altered pharmacokinetics of OATP1B1 substrate drugs and may have increased likelihood of adverse drug effects such as statin-associated musculoskeletal symptoms.Competing Interest StatementM.L. is a board member of Genomi Solutions ltd., and Nursie Health ltd. and Springflux ltd., has received honoraria from Sunovion ltd., Orion Pharma ltd., Lundbeck, Otsuka Pharma, Recordati, Janssen and Janssen-Cilag. J.T. has participated in research projects funded by grants from Eli Lilly and Janssen-Cilag to his employing institution, has received honoraria from Eli Lilly, Evidera, Janssen-Cilag, Lundbeck, Otsuka, Mediuutiset, Sidera, and Sunovion, and is consultant to HLS Therapeutics, Orion, and WebMed Global. A.V.A is an employee and shareholder of Abomics, a company providing pharmacogenetic consultation services. The other authors declare no conflict of interest.Funding StatementThe SUPER-Finland study was funded by The Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, Boston, USA. K.H. has received funding from The Ministry of Social Affairs and Health Finland, through the developmental fund for Niuvanniemi Hospital, Kuopio, Finland, The Finnish Cultural Foundation, Helsinki, Finland, The Finnish Foundation for Psychiatric Research, Helsinki, Finland, The Social Insurance Institution of Finland, Helsinki, Finland, The Emil Aaltonen Foundation, Tampere, Finland, The Academy of Finland, Helsinki, Finland and The Yrjo Jahnsson Foundation (20207277), Helsinki, Finland. W.K. was funded by The Finnish Cultural Foundation, Helsinki, Finland and The Academy of Finland (332949), Helsinki, Finland. M.L. has received funding from The Finnish Medical Foundation, Helsinki, Finland and The Emil Aaltonen Foundation, Tampere, Finland. J.L. has received funding from The Finnish Medical Foundation, Helsinki, Finland and The Finnish Foundation for Psychiatric Research, Helsinki, Finland. M.H. has received funding from The Academy of Finland (310295), Helsinki, Finland. A.V.A. has received funding from The Orion Research Foundation, Espoo, Finland, The Juho Vainio Foundation, Helsinki, Finland and The Finnish Post Doc Pool. M.N. was funded by The European Research Council Consolidator Grant (grant agreement ID: 725249). The School of Pharmacy mass spectrometry laboratory in Kuopio is supported by Biocenter Kuopio and Biocenter Finland.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Coordinating Ethics Committee of the The Hospital District of Helsinki and Uusimaa (HUS) gave a favorable ethics statement (202/13/03/00/15) for the SUPER-Finland study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe computer code used in the analysis of this study is available from the corresponding author on reasonable request and the SUPER-Finland study data is available from THL Biobank when released from the original study. ER -